Mundipharma introduces new BETADINETM Cold Defence to quickly and effectively tackle common colds
New BETADINETM Cold Defence exhibits antiviral properties1,2 and found to combat symptoms and reduce duration of common cold by 2 days3,4
Millions of people all over the world will be suffering from common cold symptoms after contracting a cold this winter, particularly in the Middle East when the cooler temperatures can catch many people off-guard leaving them prone to bouts of seasonal sickness. The symptoms of a common cold include sneezing, runny nose, headache, and general malaise, with around half of sufferers also experiencing a sore throat and coughing5.
Each year children can suffer from up to five colds with two to three colds affecting adults, which results in time off from school or work and considerable discomfort for the patient5.
As part of its commitment to tackling some of the most common healthcare issues affecting people of all ages, Mundipharma has introduced BETADINETM Cold Defence nasal sprays for adults and children to its extensive portfolio of proven effective medicines.
BETADINETM Cold Defence has been found to be effective in the treatment of common colds, fighting viruses* and shortening both the severity of symptoms and the duration of cold in patients by up to two days.3,4,6
In addition, the use of BETADINETM Cold Defence at early signs of cold symptoms can help to reduce relapses of virus-related common cold symptoms, meaning patients not only recover quicker, but also reducing the rate of potentially falling ill again.3,4,6
BETADINETM Cold Defence draws its virus-fighting properties from Carragelose, a key natural ingredient. Derived from red algae, CarrageloseTM acts as a natural physical barrier against viruses that can cause the common cold.7
This natural ingredient is proven to be safe** to use by all members of society, including children from one year of age, pregnant*** women.4,6-8
Dr. Ashraf Allam, VP of Mundipharma Middle East, Turkey and Africa region, said: “Colds caused by viruses are very common, especially at this time of the year, and are also extremely unpleasant. By introducing BETADINE TM Cold Defence, Mundipharma tackles the early stages of the virus’ lifecycle helping patients to recover faster.”
BETADINETM Cold Defence nasal sprays are preservative- and steroid-free and recognized safe** by the US Food and Drug Administration7,8
New BETADINETM Cold Defence nasal sprays for adults and children are now available in UAE pharmacies.
* In vitro, Iota-Carrageenan has shown activity against Human rhinovirus (HRV1A, HRV2, HRV8, HRV14, HRV16, HRV83 and HRV84) and Human Influenza A virus (including pandemic H1N1/2009 )1,2
** Carrageenan is widely use in the food industry and has GRAS (Generally Recognized as Safe) status by FDA. 8
*** Betadine Cold Defence can be used during pregnancy under the advice of a doctor. 7
TM: BETADINE is a trademark of Mundipharma
TM: CARRAGELOSE is a Trademark of Marinomed, used under License
Mundipharma and its network of privately owned Independent Associated Companies (IACs) is dedicated to alleviating human suffering and improving quality of life for the human race. The Mundipharma story, spanning over six decades brings together a visionary approach and a pioneering spirit – what is best told through its patients, employees and the communities across six continents in which they serve. Mundipharma is focused on business transformation by leveraging global leadership in pain and, through a shared spirit of innovation, building a growing presence in antisepsis, respiratory, oncology, ophthalmology, consumer healthcare and other specialty areas.
For more information, please visit: www.mundipharma.ae
1– Grassauer A. et al. Iota-Carrageenan is a potent inhibitor of rhinovirus infection. Virology Journal 2008, 5:107.
2- Leibbrandt A et al. (2010) Iota-Carrageenan Is a Potent Inhibitor of Influenza A Virus Infection. PLoS One. 2010;5(12):e14320.
3- Ludwig M. et al. Efficacy of a Carrageenan nasal spray in patients with common cold: A randomized controlled trial. Respir Res. 2013;14(1):124.
4- Fazekas T. et al. Lessons learned from a double-blind randomized placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold. BMC Complementary and Alternative Medicine 2012; 12: 147
5-Respiratory tract infections and antibiotic prescribing guidelines, Dubai Health Authority, 2015.Avaialable at: http://www.isahd.ae/content/docs/Dubai%20Standards%20of%20Care%20for%20Upper%20Respiratory%20Tract%20Infections.pdf. Accessed 23 January 2019.
6-Koenighofer M. et al. Carrageenan nasal spray in virus confirmed common cold:individual patient data analysis of two randomized controlled trials. Multidisciplinary Respiratory Medicine 2014;9:57.
7-Betadine Cold Defence Children and Adults Prescribing Information
8- Accessdata.fda.gov. (2018). SCOGS (Select Committee on GRAS Substances). Available at: https://www.accessdata.fda.gov/scripts/fdcc/?set=SCOGS&sort=Sortsubstance&order=ASC&startrow=1&type=basic&search=carrageenan. Accessed 23 January 2019.